CELLPROTHERA
CellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). The clinical outcome indicated an excellent safety profile associated with outstanding clinical benefits. The innovative approach developed by CellProthera is viewed by experts as one of the most effective to treat AMI and prevent secondary congestive heart failure (CHF).
CELLPROTHERA
Industry:
Biotechnology Health Care Medical
Founded:
2008-01-01
Address:
Mulhouse, Alsace, France
Country:
France
Website Url:
http://www.cellprothera.com
Total Employee:
11+
Status:
Active
Contact:
+33369719771
Total Funding:
8.4 M EUR
Technology used in webpage:
Euro IPv6 3 To 9 CcTLD Redirects
Current Employees Featured
Founder
Investors List
Alsace Business Angels
Alsace Business Angels investment in Seed Round - CellProthera
Official Site Inspections
http://www.cellprothera.com Semrush global rank: 7.49 M Semrush visits lastest month: 472
- Host name: cluster007.ovh.net
- IP address: 213.186.33.18
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "CellProthera"
CellProthera | Corporate
The good results of the Proof of Concept Trial led both Philippe HENON and Jean-Claude JELSCH to found CellProthera in 2008 whose objectives are to develop and bring to patients …See details»
CellProthera - Crunchbase Company Profile & Funding
CellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). …See details»
CellProthera | Pionnier de la Thérapie Régénératrice Cardiaque
Aug 31, 2024 Regenerative Medicine emerges as a new breakthrough model of medicine that provides a therapeutic solution to regenerate both structurally and functionally the damaged …See details»
CellProthera Company Profile 2024: Valuation, Funding …
CellProthera General Information Description. Operator of a medical biotech company intended to develop cell therapies for heart muscles. The company offers a treatment alternative based on the structural and functional …See details»
CellProthera SAS - LinkedIn
CellProthera, a biotechnological company, has developed a unique therapeutic technique which enables the structural and functional regeneration of severe post-infarctus cardiac lesions. …See details»
CellProthera - VentureRadar
CellProthera is a medical biotech company founded in 2008 in Mulhouse (France). Its activity is currently focused on the development of a revolutionary therapeutic approach allowing the …See details»
New governance at CellProthera
Aug 31, 2024 Matthieu de Kalbermatten nominated as CEO. MULHOUSE, France–(BUSINESS WIRE)–CellProthera, which offers the most advanced cell therapy for the regeneration of the …See details»
CellProthera Company Profile - Office Locations, Competitors
CellProthera is a medical biotech company founded in 2008 in Mulhouse (France). Its activity is currently focused on the development of a revolutionary therapeutic approach allowing the …See details»
CellProthera - Contacts, Employees, Board Members, Advisors
CellProthera is a medical biotech company based in Mulhouse, France.See details»
Interview with CELLPROTHERA, the regenerative medicine pioneer
Apr 2, 2015 CellProthera is a medical biotech company founded in 2008 in Mulhouse, France. The young innovative company focuses on the use of blood peripheral stem cells. …See details»
CellProthera SAS
About CellProthera CellProthera is a regenerative cell therapy developer specializing in cardiovascular diseases with a leading program in myocardial infarction. CellProthera has …See details»
CellProthera | Drug Discovery News
Organization profile for CellProthera on Drug Discovery News. The long-term PERFECT observational study follows patients from successful Phase I/IIb of ProtheraCytes for the repair …See details»
BioCardia and CellProthera Enhance Collaboration for …
Feb 1, 2023 CellProthera has developed a unique GMP-compliant cell expansion process as well as a proprietary automation technology for in vitro production of large quantity of purified, …See details»
CellProthera: the biotech using cell therapy to mend broken hearts
Oct 5, 2023 CellProthera will continue this partnership as it moves into further clinical study. Matthieu de Kalbermatten, CEO of CellProthera, said: “The treatment of our final patient within …See details»
Science & Technology - CellProthera
CellProthera chose early on to invest in the development of an automation technology to guarantee a consistent level of quality across multiple production sites, for each patient and at …See details»
CellProthera inches closer to Phase III trial for heart attack cell ...
Aug 30, 2024 CellProthera has developed technology that allows larger quantities of cells to be implanted back into the patient. The company also uses an intramyocardial injection route, …See details»
CellProthera announces positive Phase I/IIb data for ProtheraCytes ...
Mulhouse, France, May 14, 2024, 11:00am CET – CellProthera, a regenerative cell therapy company developing breakthrough treatments for ischemic diseases, announced positive …See details»
BioCardia and CellProthera Enhance Collaboration for
Feb 1, 2023 CellProthera Media Contact: IB Communications Tel +44 (0)20 89434685 [email protected]. BioCardia Media Contact: Anne Laluc [email protected], …See details»
Scoop: CellProthera eyes $30M round for PhIII trial of cell therapy …
Nov 15, 2023 CellProthera plans to raise around $30 million in its first major fundraise to help advance its lead regenerative cell therapy program for patients who have recently experienced …See details»
CellProthera | Pipeline
MEDICAL NEED. 87 % of all strokes are ischemic stroke; 2 nd most common cause of death worldwide; RATIONALE FOR CD34+ stem cells Administration of autologous CD34+ stem …See details»